nodes	percent_of_prediction	percent_of_DWPC	metapath
Atomoxetine—HTR6—Alzheimer's disease	0.238	0.514	CbGaD
Atomoxetine—HTR2A—Donepezil—Alzheimer's disease	0.099	0.338	CbGbCtD
Atomoxetine—SLC6A4—Alzheimer's disease	0.091	0.197	CbGaD
Atomoxetine—HTR2A—Alzheimer's disease	0.0699	0.151	CbGaD
Atomoxetine—CYP2D6—Alzheimer's disease	0.0639	0.138	CbGaD
Atomoxetine—CYP2D6—Rivastigmine—Alzheimer's disease	0.0412	0.141	CbGbCtD
Atomoxetine—CYP2C19—Memantine—Alzheimer's disease	0.0376	0.128	CbGbCtD
Atomoxetine—CYP2D6—Donepezil—Alzheimer's disease	0.0329	0.113	CbGbCtD
Atomoxetine—CYP3A4—Rivastigmine—Alzheimer's disease	0.0262	0.0895	CbGbCtD
Atomoxetine—CYP2D6—Galantamine—Alzheimer's disease	0.0212	0.0725	CbGbCtD
Atomoxetine—CYP3A4—Donepezil—Alzheimer's disease	0.0209	0.0716	CbGbCtD
Atomoxetine—CYP3A4—Galantamine—Alzheimer's disease	0.0135	0.0461	CbGbCtD
Atomoxetine—HTR2C—choroid plexus—Alzheimer's disease	0.0083	0.137	CbGeAlD
Atomoxetine—SLC6A2—locus ceruleus—Alzheimer's disease	0.00428	0.0704	CbGeAlD
Atomoxetine—HTR2A—choroid plexus—Alzheimer's disease	0.00416	0.0685	CbGeAlD
Atomoxetine—HTR2A—locus ceruleus—Alzheimer's disease	0.00257	0.0423	CbGeAlD
Atomoxetine—HTR1B—telencephalic ventricle—Alzheimer's disease	0.00254	0.0417	CbGeAlD
Atomoxetine—SLC6A3—telencephalic ventricle—Alzheimer's disease	0.00252	0.0414	CbGeAlD
Atomoxetine—HTR1D—telencephalic ventricle—Alzheimer's disease	0.00246	0.0404	CbGeAlD
Atomoxetine—HTR2C—telencephalic ventricle—Alzheimer's disease	0.00243	0.04	CbGeAlD
Atomoxetine—HTR2A—cerebellar cortex—Alzheimer's disease	0.0021	0.0345	CbGeAlD
Atomoxetine—NPY1R—forebrain—Alzheimer's disease	0.00156	0.0257	CbGeAlD
Atomoxetine—NPY1R—telencephalon—Alzheimer's disease	0.00144	0.0236	CbGeAlD
Atomoxetine—HTR1B—blood vessel—Alzheimer's disease	0.00126	0.0207	CbGeAlD
Atomoxetine—HTR2A—telencephalic ventricle—Alzheimer's disease	0.00122	0.0201	CbGeAlD
Atomoxetine—HTR1D—blood vessel—Alzheimer's disease	0.00122	0.02	CbGeAlD
Atomoxetine—HTR6—forebrain—Alzheimer's disease	0.0011	0.0181	CbGeAlD
Atomoxetine—HTR6—telencephalon—Alzheimer's disease	0.00101	0.0166	CbGeAlD
Atomoxetine—NPY1R—nervous system—Alzheimer's disease	0.000848	0.014	CbGeAlD
Atomoxetine—NPY1R—central nervous system—Alzheimer's disease	0.000816	0.0134	CbGeAlD
Atomoxetine—HTR1B—forebrain—Alzheimer's disease	0.000662	0.0109	CbGeAlD
Atomoxetine—SLC6A3—forebrain—Alzheimer's disease	0.000657	0.0108	CbGeAlD
Atomoxetine—NPY1R—brain—Alzheimer's disease	0.000648	0.0107	CbGeAlD
Atomoxetine—HTR1D—forebrain—Alzheimer's disease	0.000641	0.0106	CbGeAlD
Atomoxetine—HTR2C—forebrain—Alzheimer's disease	0.000635	0.0105	CbGeAlD
Atomoxetine—HTR1B—telencephalon—Alzheimer's disease	0.000609	0.01	CbGeAlD
Atomoxetine—SLC6A3—telencephalon—Alzheimer's disease	0.000604	0.00994	CbGeAlD
Atomoxetine—HTR2A—blood vessel—Alzheimer's disease	0.000604	0.00994	CbGeAlD
Atomoxetine—SLC6A4—forebrain—Alzheimer's disease	0.000602	0.00991	CbGeAlD
Atomoxetine—HTR6—nervous system—Alzheimer's disease	0.000596	0.00982	CbGeAlD
Atomoxetine—HTR1D—telencephalon—Alzheimer's disease	0.00059	0.00971	CbGeAlD
Atomoxetine—HTR2C—telencephalon—Alzheimer's disease	0.000584	0.00961	CbGeAlD
Atomoxetine—HTR6—central nervous system—Alzheimer's disease	0.000574	0.00945	CbGeAlD
Atomoxetine—SLC6A4—telencephalon—Alzheimer's disease	0.000553	0.00911	CbGeAlD
Atomoxetine—SLC6A2—forebrain—Alzheimer's disease	0.00053	0.00872	CbGeAlD
Atomoxetine—SLC6A2—telencephalon—Alzheimer's disease	0.000487	0.00802	CbGeAlD
Atomoxetine—HTR6—brain—Alzheimer's disease	0.000456	0.00751	CbGeAlD
Atomoxetine—HTR2A—embryo—Alzheimer's disease	0.00036	0.00593	CbGeAlD
Atomoxetine—HTR1B—nervous system—Alzheimer's disease	0.00036	0.00592	CbGeAlD
Atomoxetine—SLC6A3—nervous system—Alzheimer's disease	0.000357	0.00587	CbGeAlD
Atomoxetine—HTR1D—nervous system—Alzheimer's disease	0.000348	0.00573	CbGeAlD
Atomoxetine—HTR1B—central nervous system—Alzheimer's disease	0.000346	0.0057	CbGeAlD
Atomoxetine—HTR2C—nervous system—Alzheimer's disease	0.000345	0.00567	CbGeAlD
Atomoxetine—SLC6A3—central nervous system—Alzheimer's disease	0.000343	0.00565	CbGeAlD
Atomoxetine—SLC6A3—cerebellum—Alzheimer's disease	0.000336	0.00552	CbGeAlD
Atomoxetine—HTR1D—central nervous system—Alzheimer's disease	0.000335	0.00552	CbGeAlD
Atomoxetine—HTR2C—central nervous system—Alzheimer's disease	0.000332	0.00546	CbGeAlD
Atomoxetine—SLC6A4—nervous system—Alzheimer's disease	0.000327	0.00538	CbGeAlD
Atomoxetine—HTR2A—forebrain—Alzheimer's disease	0.000319	0.00524	CbGeAlD
Atomoxetine—Duloxetine—HTR6—Alzheimer's disease	0.000318	0.0915	CrCbGaD
Atomoxetine—SLC6A4—central nervous system—Alzheimer's disease	0.000315	0.00518	CbGeAlD
Atomoxetine—Flatulence—Galantamine—Alzheimer's disease	0.000308	0.00247	CcSEcCtD
Atomoxetine—Sweating increased—Memantine—Alzheimer's disease	0.000307	0.00247	CcSEcCtD
Atomoxetine—Tension—Galantamine—Alzheimer's disease	0.000307	0.00246	CcSEcCtD
Atomoxetine—Dysgeusia—Galantamine—Alzheimer's disease	0.000306	0.00245	CcSEcCtD
Atomoxetine—Nervousness—Galantamine—Alzheimer's disease	0.000304	0.00243	CcSEcCtD
Atomoxetine—Back pain—Galantamine—Alzheimer's disease	0.000302	0.00242	CcSEcCtD
Atomoxetine—Conjunctivitis—Donepezil—Alzheimer's disease	0.000301	0.00242	CcSEcCtD
Atomoxetine—Sweating increased—Rivastigmine—Alzheimer's disease	0.000301	0.00241	CcSEcCtD
Atomoxetine—Muscle spasms—Galantamine—Alzheimer's disease	0.0003	0.00241	CcSEcCtD
Atomoxetine—Dysuria—Memantine—Alzheimer's disease	0.000295	0.00237	CcSEcCtD
Atomoxetine—Vision blurred—Galantamine—Alzheimer's disease	0.000295	0.00236	CcSEcCtD
Atomoxetine—Upper respiratory tract infection—Memantine—Alzheimer's disease	0.000293	0.00235	CcSEcCtD
Atomoxetine—HTR2A—telencephalon—Alzheimer's disease	0.000293	0.00482	CbGeAlD
Atomoxetine—Tremor—Galantamine—Alzheimer's disease	0.000293	0.00235	CcSEcCtD
Atomoxetine—Pollakiuria—Memantine—Alzheimer's disease	0.000292	0.00234	CcSEcCtD
Atomoxetine—Erectile dysfunction—Memantine—Alzheimer's disease	0.000291	0.00233	CcSEcCtD
Atomoxetine—CYP2D6—forebrain—Alzheimer's disease	0.00029	0.00478	CbGeAlD
Atomoxetine—Dysuria—Rivastigmine—Alzheimer's disease	0.000289	0.00232	CcSEcCtD
Atomoxetine—SLC6A2—nervous system—Alzheimer's disease	0.000288	0.00474	CbGeAlD
Atomoxetine—Agitation—Galantamine—Alzheimer's disease	0.000287	0.0023	CcSEcCtD
Atomoxetine—Upper respiratory tract infection—Rivastigmine—Alzheimer's disease	0.000287	0.0023	CcSEcCtD
Atomoxetine—Weight decreased—Memantine—Alzheimer's disease	0.000286	0.00229	CcSEcCtD
Atomoxetine—Pollakiuria—Rivastigmine—Alzheimer's disease	0.000285	0.00229	CcSEcCtD
Atomoxetine—Erectile dysfunction—Rivastigmine—Alzheimer's disease	0.000284	0.00228	CcSEcCtD
Atomoxetine—Infestation NOS—Memantine—Alzheimer's disease	0.000281	0.00226	CcSEcCtD
Atomoxetine—Infestation—Memantine—Alzheimer's disease	0.000281	0.00226	CcSEcCtD
Atomoxetine—Vertigo—Galantamine—Alzheimer's disease	0.000281	0.00225	CcSEcCtD
Atomoxetine—Depression—Memantine—Alzheimer's disease	0.000281	0.00225	CcSEcCtD
Atomoxetine—Syncope—Galantamine—Alzheimer's disease	0.00028	0.00225	CcSEcCtD
Atomoxetine—Weight decreased—Rivastigmine—Alzheimer's disease	0.000279	0.00224	CcSEcCtD
Atomoxetine—SLC6A2—central nervous system—Alzheimer's disease	0.000277	0.00456	CbGeAlD
Atomoxetine—Hypoaesthesia—Donepezil—Alzheimer's disease	0.000277	0.00222	CcSEcCtD
Atomoxetine—Hallucination—Donepezil—Alzheimer's disease	0.000277	0.00222	CcSEcCtD
Atomoxetine—Palpitations—Galantamine—Alzheimer's disease	0.000276	0.00221	CcSEcCtD
Atomoxetine—Infestation NOS—Rivastigmine—Alzheimer's disease	0.000275	0.00221	CcSEcCtD
Atomoxetine—Infestation—Rivastigmine—Alzheimer's disease	0.000275	0.00221	CcSEcCtD
Atomoxetine—HTR1B—brain—Alzheimer's disease	0.000275	0.00452	CbGeAlD
Atomoxetine—Urinary tract disorder—Donepezil—Alzheimer's disease	0.000275	0.0022	CcSEcCtD
Atomoxetine—Loss of consciousness—Galantamine—Alzheimer's disease	0.000275	0.0022	CcSEcCtD
Atomoxetine—Depression—Rivastigmine—Alzheimer's disease	0.000275	0.0022	CcSEcCtD
Atomoxetine—Conjunctivitis—Memantine—Alzheimer's disease	0.000274	0.00219	CcSEcCtD
Atomoxetine—Urethral disorder—Donepezil—Alzheimer's disease	0.000273	0.00219	CcSEcCtD
Atomoxetine—Cough—Galantamine—Alzheimer's disease	0.000273	0.00219	CcSEcCtD
Atomoxetine—SLC6A3—brain—Alzheimer's disease	0.000273	0.00449	CbGeAlD
Atomoxetine—Convulsion—Galantamine—Alzheimer's disease	0.000271	0.00217	CcSEcCtD
Atomoxetine—Conjunctivitis—Rivastigmine—Alzheimer's disease	0.000268	0.00215	CcSEcCtD
Atomoxetine—CYP2D6—telencephalon—Alzheimer's disease	0.000267	0.00439	CbGeAlD
Atomoxetine—Arthralgia—Galantamine—Alzheimer's disease	0.000266	0.00213	CcSEcCtD
Atomoxetine—Chest pain—Galantamine—Alzheimer's disease	0.000266	0.00213	CcSEcCtD
Atomoxetine—Myalgia—Galantamine—Alzheimer's disease	0.000266	0.00213	CcSEcCtD
Atomoxetine—HTR1D—brain—Alzheimer's disease	0.000266	0.00438	CbGeAlD
Atomoxetine—Anxiety—Galantamine—Alzheimer's disease	0.000265	0.00213	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Galantamine—Alzheimer's disease	0.000264	0.00212	CcSEcCtD
Atomoxetine—Sinusitis—Memantine—Alzheimer's disease	0.000264	0.00212	CcSEcCtD
Atomoxetine—HTR2C—brain—Alzheimer's disease	0.000263	0.00434	CbGeAlD
Atomoxetine—Dry mouth—Galantamine—Alzheimer's disease	0.00026	0.00209	CcSEcCtD
Atomoxetine—Sinusitis—Rivastigmine—Alzheimer's disease	0.000258	0.00207	CcSEcCtD
Atomoxetine—Hallucination—Memantine—Alzheimer's disease	0.000251	0.00202	CcSEcCtD
Atomoxetine—Hypoaesthesia—Memantine—Alzheimer's disease	0.000251	0.00202	CcSEcCtD
Atomoxetine—Shock—Galantamine—Alzheimer's disease	0.000251	0.00201	CcSEcCtD
Atomoxetine—Nervous system disorder—Galantamine—Alzheimer's disease	0.00025	0.00201	CcSEcCtD
Atomoxetine—SLC6A4—brain—Alzheimer's disease	0.00025	0.00411	CbGeAlD
Atomoxetine—Chills—Donepezil—Alzheimer's disease	0.00025	0.002	CcSEcCtD
Atomoxetine—Urinary tract disorder—Memantine—Alzheimer's disease	0.000249	0.002	CcSEcCtD
Atomoxetine—Tachycardia—Galantamine—Alzheimer's disease	0.000249	0.002	CcSEcCtD
Atomoxetine—Skin disorder—Galantamine—Alzheimer's disease	0.000248	0.00199	CcSEcCtD
Atomoxetine—Urethral disorder—Memantine—Alzheimer's disease	0.000248	0.00199	CcSEcCtD
Atomoxetine—Ephedrine—ACHE—Alzheimer's disease	0.000248	0.0713	CrCbGaD
Atomoxetine—Hyperhidrosis—Galantamine—Alzheimer's disease	0.000247	0.00198	CcSEcCtD
Atomoxetine—Hallucination—Rivastigmine—Alzheimer's disease	0.000246	0.00197	CcSEcCtD
Atomoxetine—Hypoaesthesia—Rivastigmine—Alzheimer's disease	0.000246	0.00197	CcSEcCtD
Atomoxetine—Urinary tract disorder—Rivastigmine—Alzheimer's disease	0.000244	0.00196	CcSEcCtD
Atomoxetine—Mental disorder—Donepezil—Alzheimer's disease	0.000244	0.00195	CcSEcCtD
Atomoxetine—Anorexia—Galantamine—Alzheimer's disease	0.000243	0.00195	CcSEcCtD
Atomoxetine—Urethral disorder—Rivastigmine—Alzheimer's disease	0.000242	0.00194	CcSEcCtD
Atomoxetine—Malnutrition—Donepezil—Alzheimer's disease	0.000242	0.00194	CcSEcCtD
Atomoxetine—Flatulence—Donepezil—Alzheimer's disease	0.000239	0.00191	CcSEcCtD
Atomoxetine—Tension—Donepezil—Alzheimer's disease	0.000238	0.00191	CcSEcCtD
Atomoxetine—Dysgeusia—Donepezil—Alzheimer's disease	0.000237	0.0019	CcSEcCtD
Atomoxetine—Nervousness—Donepezil—Alzheimer's disease	0.000235	0.00189	CcSEcCtD
Atomoxetine—Cardiac disorder—Memantine—Alzheimer's disease	0.000234	0.00188	CcSEcCtD
Atomoxetine—Flushing—Memantine—Alzheimer's disease	0.000234	0.00188	CcSEcCtD
Atomoxetine—Back pain—Donepezil—Alzheimer's disease	0.000234	0.00188	CcSEcCtD
Atomoxetine—Muscle spasms—Donepezil—Alzheimer's disease	0.000233	0.00187	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Galantamine—Alzheimer's disease	0.000232	0.00186	CcSEcCtD
Atomoxetine—Insomnia—Galantamine—Alzheimer's disease	0.000231	0.00185	CcSEcCtD
Atomoxetine—Flushing—Rivastigmine—Alzheimer's disease	0.000229	0.00184	CcSEcCtD
Atomoxetine—Cardiac disorder—Rivastigmine—Alzheimer's disease	0.000229	0.00184	CcSEcCtD
Atomoxetine—Angiopathy—Memantine—Alzheimer's disease	0.000229	0.00184	CcSEcCtD
Atomoxetine—Paraesthesia—Galantamine—Alzheimer's disease	0.000229	0.00184	CcSEcCtD
Atomoxetine—Vision blurred—Donepezil—Alzheimer's disease	0.000228	0.00183	CcSEcCtD
Atomoxetine—Mediastinal disorder—Memantine—Alzheimer's disease	0.000228	0.00183	CcSEcCtD
Atomoxetine—Tremor—Donepezil—Alzheimer's disease	0.000227	0.00182	CcSEcCtD
Atomoxetine—Somnolence—Galantamine—Alzheimer's disease	0.000227	0.00182	CcSEcCtD
Atomoxetine—Chills—Memantine—Alzheimer's disease	0.000227	0.00182	CcSEcCtD
Atomoxetine—Dyspepsia—Galantamine—Alzheimer's disease	0.000225	0.0018	CcSEcCtD
Atomoxetine—Angiopathy—Rivastigmine—Alzheimer's disease	0.000224	0.0018	CcSEcCtD
Atomoxetine—Mediastinal disorder—Rivastigmine—Alzheimer's disease	0.000223	0.00179	CcSEcCtD
Atomoxetine—Agitation—Donepezil—Alzheimer's disease	0.000223	0.00178	CcSEcCtD
Atomoxetine—Chills—Rivastigmine—Alzheimer's disease	0.000222	0.00178	CcSEcCtD
Atomoxetine—Decreased appetite—Galantamine—Alzheimer's disease	0.000222	0.00178	CcSEcCtD
Atomoxetine—Mental disorder—Memantine—Alzheimer's disease	0.000221	0.00177	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Galantamine—Alzheimer's disease	0.00022	0.00177	CcSEcCtD
Atomoxetine—Malnutrition—Memantine—Alzheimer's disease	0.00022	0.00176	CcSEcCtD
Atomoxetine—Fatigue—Galantamine—Alzheimer's disease	0.00022	0.00176	CcSEcCtD
Atomoxetine—SLC6A2—brain—Alzheimer's disease	0.00022	0.00362	CbGeAlD
Atomoxetine—Constipation—Galantamine—Alzheimer's disease	0.000218	0.00175	CcSEcCtD
Atomoxetine—Vertigo—Donepezil—Alzheimer's disease	0.000218	0.00175	CcSEcCtD
Atomoxetine—Syncope—Donepezil—Alzheimer's disease	0.000217	0.00174	CcSEcCtD
Atomoxetine—Flatulence—Memantine—Alzheimer's disease	0.000217	0.00174	CcSEcCtD
Atomoxetine—Mental disorder—Rivastigmine—Alzheimer's disease	0.000217	0.00174	CcSEcCtD
Atomoxetine—Tension—Memantine—Alzheimer's disease	0.000216	0.00173	CcSEcCtD
Atomoxetine—Dysgeusia—Memantine—Alzheimer's disease	0.000215	0.00173	CcSEcCtD
Atomoxetine—Malnutrition—Rivastigmine—Alzheimer's disease	0.000215	0.00173	CcSEcCtD
Atomoxetine—Nervousness—Memantine—Alzheimer's disease	0.000214	0.00171	CcSEcCtD
Atomoxetine—Loss of consciousness—Donepezil—Alzheimer's disease	0.000213	0.00171	CcSEcCtD
Atomoxetine—Back pain—Memantine—Alzheimer's disease	0.000213	0.00171	CcSEcCtD
Atomoxetine—Flatulence—Rivastigmine—Alzheimer's disease	0.000212	0.0017	CcSEcCtD
Atomoxetine—Cough—Donepezil—Alzheimer's disease	0.000211	0.00169	CcSEcCtD
Atomoxetine—Tension—Rivastigmine—Alzheimer's disease	0.000211	0.00169	CcSEcCtD
Atomoxetine—Dysgeusia—Rivastigmine—Alzheimer's disease	0.000211	0.00169	CcSEcCtD
Atomoxetine—Feeling abnormal—Galantamine—Alzheimer's disease	0.00021	0.00169	CcSEcCtD
Atomoxetine—Convulsion—Donepezil—Alzheimer's disease	0.00021	0.00168	CcSEcCtD
Atomoxetine—Nervousness—Rivastigmine—Alzheimer's disease	0.000209	0.00168	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Galantamine—Alzheimer's disease	0.000209	0.00167	CcSEcCtD
Atomoxetine—Back pain—Rivastigmine—Alzheimer's disease	0.000208	0.00167	CcSEcCtD
Atomoxetine—Vision blurred—Memantine—Alzheimer's disease	0.000207	0.00166	CcSEcCtD
Atomoxetine—Muscle spasms—Rivastigmine—Alzheimer's disease	0.000207	0.00166	CcSEcCtD
Atomoxetine—Arthralgia—Donepezil—Alzheimer's disease	0.000206	0.00165	CcSEcCtD
Atomoxetine—Myalgia—Donepezil—Alzheimer's disease	0.000206	0.00165	CcSEcCtD
Atomoxetine—Chest pain—Donepezil—Alzheimer's disease	0.000206	0.00165	CcSEcCtD
Atomoxetine—Tremor—Memantine—Alzheimer's disease	0.000206	0.00165	CcSEcCtD
Atomoxetine—Anxiety—Donepezil—Alzheimer's disease	0.000205	0.00165	CcSEcCtD
Atomoxetine—Vision blurred—Rivastigmine—Alzheimer's disease	0.000203	0.00163	CcSEcCtD
Atomoxetine—Agitation—Memantine—Alzheimer's disease	0.000202	0.00162	CcSEcCtD
Atomoxetine—Dry mouth—Donepezil—Alzheimer's disease	0.000202	0.00162	CcSEcCtD
Atomoxetine—Body temperature increased—Galantamine—Alzheimer's disease	0.000202	0.00162	CcSEcCtD
Atomoxetine—Abdominal pain—Galantamine—Alzheimer's disease	0.000202	0.00162	CcSEcCtD
Atomoxetine—Tremor—Rivastigmine—Alzheimer's disease	0.000202	0.00162	CcSEcCtD
Atomoxetine—Agitation—Rivastigmine—Alzheimer's disease	0.000198	0.00159	CcSEcCtD
Atomoxetine—Vertigo—Memantine—Alzheimer's disease	0.000198	0.00158	CcSEcCtD
Atomoxetine—Syncope—Memantine—Alzheimer's disease	0.000197	0.00158	CcSEcCtD
Atomoxetine—Infection—Donepezil—Alzheimer's disease	0.000196	0.00157	CcSEcCtD
Atomoxetine—Shock—Donepezil—Alzheimer's disease	0.000194	0.00156	CcSEcCtD
Atomoxetine—Palpitations—Memantine—Alzheimer's disease	0.000194	0.00156	CcSEcCtD
Atomoxetine—Nervous system disorder—Donepezil—Alzheimer's disease	0.000194	0.00155	CcSEcCtD
Atomoxetine—Vertigo—Rivastigmine—Alzheimer's disease	0.000193	0.00155	CcSEcCtD
Atomoxetine—Loss of consciousness—Memantine—Alzheimer's disease	0.000193	0.00155	CcSEcCtD
Atomoxetine—Syncope—Rivastigmine—Alzheimer's disease	0.000193	0.00155	CcSEcCtD
Atomoxetine—Cough—Memantine—Alzheimer's disease	0.000192	0.00154	CcSEcCtD
Atomoxetine—Hyperhidrosis—Donepezil—Alzheimer's disease	0.000191	0.00153	CcSEcCtD
Atomoxetine—Convulsion—Memantine—Alzheimer's disease	0.000191	0.00153	CcSEcCtD
Atomoxetine—Palpitations—Rivastigmine—Alzheimer's disease	0.00019	0.00152	CcSEcCtD
Atomoxetine—Loss of consciousness—Rivastigmine—Alzheimer's disease	0.000189	0.00152	CcSEcCtD
Atomoxetine—Anorexia—Donepezil—Alzheimer's disease	0.000188	0.00151	CcSEcCtD
Atomoxetine—Cough—Rivastigmine—Alzheimer's disease	0.000188	0.00151	CcSEcCtD
Atomoxetine—Myalgia—Memantine—Alzheimer's disease	0.000187	0.0015	CcSEcCtD
Atomoxetine—Chest pain—Memantine—Alzheimer's disease	0.000187	0.0015	CcSEcCtD
Atomoxetine—Arthralgia—Memantine—Alzheimer's disease	0.000187	0.0015	CcSEcCtD
Atomoxetine—Anxiety—Memantine—Alzheimer's disease	0.000187	0.0015	CcSEcCtD
Atomoxetine—Convulsion—Rivastigmine—Alzheimer's disease	0.000186	0.00149	CcSEcCtD
Atomoxetine—Myalgia—Rivastigmine—Alzheimer's disease	0.000183	0.00147	CcSEcCtD
Atomoxetine—Arthralgia—Rivastigmine—Alzheimer's disease	0.000183	0.00147	CcSEcCtD
Atomoxetine—Chest pain—Rivastigmine—Alzheimer's disease	0.000183	0.00147	CcSEcCtD
Atomoxetine—Dry mouth—Memantine—Alzheimer's disease	0.000183	0.00147	CcSEcCtD
Atomoxetine—Asthenia—Galantamine—Alzheimer's disease	0.000183	0.00147	CcSEcCtD
Atomoxetine—Anxiety—Rivastigmine—Alzheimer's disease	0.000183	0.00146	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Rivastigmine—Alzheimer's disease	0.000182	0.00146	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Donepezil—Alzheimer's disease	0.00018	0.00144	CcSEcCtD
Atomoxetine—Dry mouth—Rivastigmine—Alzheimer's disease	0.000179	0.00144	CcSEcCtD
Atomoxetine—Insomnia—Donepezil—Alzheimer's disease	0.000179	0.00143	CcSEcCtD
Atomoxetine—Infection—Memantine—Alzheimer's disease	0.000178	0.00143	CcSEcCtD
Atomoxetine—Phenoxybenzamine—CALM1—Alzheimer's disease	0.000178	0.0512	CrCbGaD
Atomoxetine—Paraesthesia—Donepezil—Alzheimer's disease	0.000177	0.00142	CcSEcCtD
Atomoxetine—Shock—Memantine—Alzheimer's disease	0.000177	0.00142	CcSEcCtD
Atomoxetine—Nervous system disorder—Memantine—Alzheimer's disease	0.000176	0.00141	CcSEcCtD
Atomoxetine—Somnolence—Donepezil—Alzheimer's disease	0.000176	0.00141	CcSEcCtD
Atomoxetine—Tachycardia—Memantine—Alzheimer's disease	0.000175	0.0014	CcSEcCtD
Atomoxetine—Diarrhoea—Galantamine—Alzheimer's disease	0.000175	0.0014	CcSEcCtD
Atomoxetine—Infection—Rivastigmine—Alzheimer's disease	0.000174	0.0014	CcSEcCtD
Atomoxetine—Skin disorder—Memantine—Alzheimer's disease	0.000174	0.0014	CcSEcCtD
Atomoxetine—Dyspepsia—Donepezil—Alzheimer's disease	0.000174	0.0014	CcSEcCtD
Atomoxetine—Hyperhidrosis—Memantine—Alzheimer's disease	0.000174	0.00139	CcSEcCtD
Atomoxetine—HTR2A—nervous system—Alzheimer's disease	0.000173	0.00285	CbGeAlD
Atomoxetine—Shock—Rivastigmine—Alzheimer's disease	0.000173	0.00139	CcSEcCtD
Atomoxetine—Nervous system disorder—Rivastigmine—Alzheimer's disease	0.000172	0.00138	CcSEcCtD
Atomoxetine—Decreased appetite—Donepezil—Alzheimer's disease	0.000172	0.00138	CcSEcCtD
Atomoxetine—Tachycardia—Rivastigmine—Alzheimer's disease	0.000171	0.00137	CcSEcCtD
Atomoxetine—Anorexia—Memantine—Alzheimer's disease	0.000171	0.00137	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Donepezil—Alzheimer's disease	0.000171	0.00137	CcSEcCtD
Atomoxetine—Skin disorder—Rivastigmine—Alzheimer's disease	0.000171	0.00137	CcSEcCtD
Atomoxetine—Fatigue—Donepezil—Alzheimer's disease	0.00017	0.00137	CcSEcCtD
Atomoxetine—Hyperhidrosis—Rivastigmine—Alzheimer's disease	0.00017	0.00136	CcSEcCtD
Atomoxetine—Constipation—Donepezil—Alzheimer's disease	0.000169	0.00136	CcSEcCtD
Atomoxetine—Pain—Donepezil—Alzheimer's disease	0.000169	0.00136	CcSEcCtD
Atomoxetine—Dizziness—Galantamine—Alzheimer's disease	0.000169	0.00135	CcSEcCtD
Atomoxetine—Anorexia—Rivastigmine—Alzheimer's disease	0.000167	0.00134	CcSEcCtD
Atomoxetine—HTR2A—central nervous system—Alzheimer's disease	0.000166	0.00274	CbGeAlD
Atomoxetine—Musculoskeletal discomfort—Memantine—Alzheimer's disease	0.000164	0.00131	CcSEcCtD
Atomoxetine—Feeling abnormal—Donepezil—Alzheimer's disease	0.000163	0.00131	CcSEcCtD
Atomoxetine—HTR2A—cerebellum—Alzheimer's disease	0.000163	0.00268	CbGeAlD
Atomoxetine—Insomnia—Memantine—Alzheimer's disease	0.000162	0.0013	CcSEcCtD
Atomoxetine—Vomiting—Galantamine—Alzheimer's disease	0.000162	0.0013	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Donepezil—Alzheimer's disease	0.000162	0.0013	CcSEcCtD
Atomoxetine—Paraesthesia—Memantine—Alzheimer's disease	0.000161	0.00129	CcSEcCtD
Atomoxetine—Rash—Galantamine—Alzheimer's disease	0.000161	0.00129	CcSEcCtD
Atomoxetine—Dermatitis—Galantamine—Alzheimer's disease	0.000161	0.00129	CcSEcCtD
Atomoxetine—CYP3A4—nervous system—Alzheimer's disease	0.00016	0.00264	CbGeAlD
Atomoxetine—Musculoskeletal discomfort—Rivastigmine—Alzheimer's disease	0.00016	0.00128	CcSEcCtD
Atomoxetine—Headache—Galantamine—Alzheimer's disease	0.00016	0.00128	CcSEcCtD
Atomoxetine—Somnolence—Memantine—Alzheimer's disease	0.00016	0.00128	CcSEcCtD
Atomoxetine—Insomnia—Rivastigmine—Alzheimer's disease	0.000159	0.00127	CcSEcCtD
Atomoxetine—Reboxetine—SLC6A4—Alzheimer's disease	0.000158	0.0455	CrCbGaD
Atomoxetine—Dyspepsia—Memantine—Alzheimer's disease	0.000158	0.00127	CcSEcCtD
Atomoxetine—Paraesthesia—Rivastigmine—Alzheimer's disease	0.000158	0.00126	CcSEcCtD
Atomoxetine—CYP2D6—nervous system—Alzheimer's disease	0.000158	0.00259	CbGeAlD
Atomoxetine—Urticaria—Donepezil—Alzheimer's disease	0.000157	0.00126	CcSEcCtD
Atomoxetine—Body temperature increased—Donepezil—Alzheimer's disease	0.000156	0.00125	CcSEcCtD
Atomoxetine—Abdominal pain—Donepezil—Alzheimer's disease	0.000156	0.00125	CcSEcCtD
Atomoxetine—Somnolence—Rivastigmine—Alzheimer's disease	0.000156	0.00125	CcSEcCtD
Atomoxetine—Decreased appetite—Memantine—Alzheimer's disease	0.000156	0.00125	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Memantine—Alzheimer's disease	0.000155	0.00124	CcSEcCtD
Atomoxetine—Fatigue—Memantine—Alzheimer's disease	0.000155	0.00124	CcSEcCtD
Atomoxetine—Dyspepsia—Rivastigmine—Alzheimer's disease	0.000155	0.00124	CcSEcCtD
Atomoxetine—CYP3A4—central nervous system—Alzheimer's disease	0.000154	0.00254	CbGeAlD
Atomoxetine—Pain—Memantine—Alzheimer's disease	0.000153	0.00123	CcSEcCtD
Atomoxetine—Constipation—Memantine—Alzheimer's disease	0.000153	0.00123	CcSEcCtD
Atomoxetine—Decreased appetite—Rivastigmine—Alzheimer's disease	0.000153	0.00122	CcSEcCtD
Atomoxetine—CYP2D6—central nervous system—Alzheimer's disease	0.000152	0.0025	CbGeAlD
Atomoxetine—Gastrointestinal disorder—Rivastigmine—Alzheimer's disease	0.000152	0.00122	CcSEcCtD
Atomoxetine—Nausea—Galantamine—Alzheimer's disease	0.000152	0.00121	CcSEcCtD
Atomoxetine—Fatigue—Rivastigmine—Alzheimer's disease	0.000151	0.00121	CcSEcCtD
Atomoxetine—Pain—Rivastigmine—Alzheimer's disease	0.00015	0.0012	CcSEcCtD
Atomoxetine—Constipation—Rivastigmine—Alzheimer's disease	0.00015	0.0012	CcSEcCtD
Atomoxetine—CYP2D6—cerebellum—Alzheimer's disease	0.000148	0.00244	CbGeAlD
Atomoxetine—Feeling abnormal—Memantine—Alzheimer's disease	0.000148	0.00119	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Memantine—Alzheimer's disease	0.000147	0.00118	CcSEcCtD
Atomoxetine—Ephedrine—BCHE—Alzheimer's disease	0.000146	0.0419	CrCbGaD
Atomoxetine—Nortriptyline—HTR6—Alzheimer's disease	0.000145	0.0419	CrCbGaD
Atomoxetine—Protriptyline—SLC6A4—Alzheimer's disease	0.000145	0.0418	CrCbGaD
Atomoxetine—Feeling abnormal—Rivastigmine—Alzheimer's disease	0.000145	0.00116	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Rivastigmine—Alzheimer's disease	0.000144	0.00115	CcSEcCtD
Atomoxetine—Urticaria—Memantine—Alzheimer's disease	0.000143	0.00114	CcSEcCtD
Atomoxetine—Body temperature increased—Memantine—Alzheimer's disease	0.000142	0.00114	CcSEcCtD
Atomoxetine—Abdominal pain—Memantine—Alzheimer's disease	0.000142	0.00114	CcSEcCtD
Atomoxetine—Asthenia—Donepezil—Alzheimer's disease	0.000142	0.00114	CcSEcCtD
Atomoxetine—Pruritus—Donepezil—Alzheimer's disease	0.00014	0.00112	CcSEcCtD
Atomoxetine—Urticaria—Rivastigmine—Alzheimer's disease	0.000139	0.00112	CcSEcCtD
Atomoxetine—Body temperature increased—Rivastigmine—Alzheimer's disease	0.000139	0.00111	CcSEcCtD
Atomoxetine—Abdominal pain—Rivastigmine—Alzheimer's disease	0.000139	0.00111	CcSEcCtD
Atomoxetine—Diarrhoea—Donepezil—Alzheimer's disease	0.000135	0.00108	CcSEcCtD
Atomoxetine—HTR2A—brain—Alzheimer's disease	0.000132	0.00218	CbGeAlD
Atomoxetine—Dizziness—Donepezil—Alzheimer's disease	0.000131	0.00105	CcSEcCtD
Atomoxetine—Asthenia—Memantine—Alzheimer's disease	0.000129	0.00103	CcSEcCtD
Atomoxetine—Pruritus—Memantine—Alzheimer's disease	0.000127	0.00102	CcSEcCtD
Atomoxetine—Asthenia—Rivastigmine—Alzheimer's disease	0.000126	0.00101	CcSEcCtD
Atomoxetine—Vomiting—Donepezil—Alzheimer's disease	0.000126	0.00101	CcSEcCtD
Atomoxetine—Rash—Donepezil—Alzheimer's disease	0.000125	0.000999	CcSEcCtD
Atomoxetine—Dermatitis—Donepezil—Alzheimer's disease	0.000125	0.000999	CcSEcCtD
Atomoxetine—Pruritus—Rivastigmine—Alzheimer's disease	0.000124	0.000996	CcSEcCtD
Atomoxetine—Headache—Donepezil—Alzheimer's disease	0.000124	0.000993	CcSEcCtD
Atomoxetine—Diarrhoea—Memantine—Alzheimer's disease	0.000123	0.000985	CcSEcCtD
Atomoxetine—Fenoprofen—PTGS1—Alzheimer's disease	0.000122	0.0351	CrCbGaD
Atomoxetine—Duloxetine—SLC6A4—Alzheimer's disease	0.000122	0.035	CrCbGaD
Atomoxetine—CYP2D6—brain—Alzheimer's disease	0.00012	0.00198	CbGeAlD
Atomoxetine—Diarrhoea—Rivastigmine—Alzheimer's disease	0.00012	0.000963	CcSEcCtD
Atomoxetine—Dizziness—Memantine—Alzheimer's disease	0.000119	0.000952	CcSEcCtD
Atomoxetine—Nausea—Donepezil—Alzheimer's disease	0.000117	0.000942	CcSEcCtD
Atomoxetine—Dizziness—Rivastigmine—Alzheimer's disease	0.000116	0.000931	CcSEcCtD
Atomoxetine—Vomiting—Memantine—Alzheimer's disease	0.000114	0.000915	CcSEcCtD
Atomoxetine—Rash—Memantine—Alzheimer's disease	0.000113	0.000907	CcSEcCtD
Atomoxetine—Dermatitis—Memantine—Alzheimer's disease	0.000113	0.000907	CcSEcCtD
Atomoxetine—Headache—Memantine—Alzheimer's disease	0.000112	0.000902	CcSEcCtD
Atomoxetine—Vomiting—Rivastigmine—Alzheimer's disease	0.000112	0.000895	CcSEcCtD
Atomoxetine—Reboxetine—CYP2D6—Alzheimer's disease	0.000111	0.032	CrCbGaD
Atomoxetine—Rash—Rivastigmine—Alzheimer's disease	0.000111	0.000888	CcSEcCtD
Atomoxetine—Dermatitis—Rivastigmine—Alzheimer's disease	0.000111	0.000887	CcSEcCtD
Atomoxetine—Headache—Rivastigmine—Alzheimer's disease	0.00011	0.000882	CcSEcCtD
Atomoxetine—Pseudoephedrine—TNF—Alzheimer's disease	0.000107	0.0308	CrCbGaD
Atomoxetine—Nausea—Memantine—Alzheimer's disease	0.000107	0.000855	CcSEcCtD
Atomoxetine—Nausea—Rivastigmine—Alzheimer's disease	0.000104	0.000836	CcSEcCtD
Atomoxetine—Protriptyline—CYP2D6—Alzheimer's disease	0.000102	0.0294	CrCbGaD
Atomoxetine—Fluoxetine—SLC6A4—Alzheimer's disease	9.92e-05	0.0286	CrCbGaD
Atomoxetine—Duloxetine—HTR2A—Alzheimer's disease	9.35e-05	0.0269	CrCbGaD
Atomoxetine—Pseudoephedrine—SLC6A4—Alzheimer's disease	8.61e-05	0.0248	CrCbGaD
Atomoxetine—Duloxetine—CYP2D6—Alzheimer's disease	8.55e-05	0.0246	CrCbGaD
Atomoxetine—Fluoxetine—HTR2A—Alzheimer's disease	7.62e-05	0.0219	CrCbGaD
Atomoxetine—Tolterodine—CYP2D6—Alzheimer's disease	7.31e-05	0.021	CrCbGaD
Atomoxetine—Ketoprofen—PTGS1—Alzheimer's disease	7.2e-05	0.0207	CrCbGaD
Atomoxetine—Maprotiline—HTR2A—Alzheimer's disease	7.12e-05	0.0205	CrCbGaD
Atomoxetine—Benzatropine—CYP2D6—Alzheimer's disease	7.03e-05	0.0202	CrCbGaD
Atomoxetine—Fenoprofen—PTGS2—Alzheimer's disease	6.98e-05	0.0201	CrCbGaD
Atomoxetine—Fluoxetine—CYP2D6—Alzheimer's disease	6.97e-05	0.0201	CrCbGaD
Atomoxetine—Maprotiline—CYP2D6—Alzheimer's disease	6.51e-05	0.0187	CrCbGaD
Atomoxetine—Propafenone—CYP2D6—Alzheimer's disease	6.21e-05	0.0179	CrCbGaD
Atomoxetine—Pseudoephedrine—CYP2D6—Alzheimer's disease	6.05e-05	0.0174	CrCbGaD
Atomoxetine—Nortriptyline—PTGS1—Alzheimer's disease	5.75e-05	0.0165	CrCbGaD
Atomoxetine—Nortriptyline—SLC6A4—Alzheimer's disease	5.57e-05	0.016	CrCbGaD
Atomoxetine—Diphenhydramine—PTGS1—Alzheimer's disease	5.31e-05	0.0153	CrCbGaD
Atomoxetine—Desipramine—SLC6A4—Alzheimer's disease	4.58e-05	0.0132	CrCbGaD
Atomoxetine—Nortriptyline—HTR2A—Alzheimer's disease	4.28e-05	0.0123	CrCbGaD
Atomoxetine—Propranolol—CYP2D6—Alzheimer's disease	4.25e-05	0.0122	CrCbGaD
Atomoxetine—Ketoprofen—PTGS2—Alzheimer's disease	4.12e-05	0.0119	CrCbGaD
Atomoxetine—Nortriptyline—CYP2D6—Alzheimer's disease	3.91e-05	0.0113	CrCbGaD
Atomoxetine—Diphenhydramine—CYP2D6—Alzheimer's disease	3.62e-05	0.0104	CrCbGaD
Atomoxetine—Desipramine—HTR2A—Alzheimer's disease	3.52e-05	0.0101	CrCbGaD
Atomoxetine—Methadone—CYP2D6—Alzheimer's disease	3.49e-05	0.0101	CrCbGaD
Atomoxetine—Desipramine—CYP2D6—Alzheimer's disease	3.22e-05	0.00927	CrCbGaD
Atomoxetine—HTR2C—Signaling by GPCR—F2—Alzheimer's disease	7.04e-06	0.000125	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MEF2C—Alzheimer's disease	7.03e-06	0.000125	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP46A1—Alzheimer's disease	7.02e-06	0.000125	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—MAOB—Alzheimer's disease	6.97e-06	0.000124	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PRKCG—Alzheimer's disease	6.95e-06	0.000124	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—LPL—Alzheimer's disease	6.95e-06	0.000124	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PLCB1—Alzheimer's disease	6.92e-06	0.000123	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PRKCG—Alzheimer's disease	6.9e-06	0.000123	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MEF2C—Alzheimer's disease	6.88e-06	0.000122	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NPS—Alzheimer's disease	6.85e-06	0.000122	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PPP3CA—Alzheimer's disease	6.82e-06	0.000121	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ND1—Alzheimer's disease	6.78e-06	0.000121	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—NGF—Alzheimer's disease	6.77e-06	0.00012	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PRKCG—Alzheimer's disease	6.75e-06	0.00012	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—F2—Alzheimer's disease	6.74e-06	0.00012	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—NGF—Alzheimer's disease	6.72e-06	0.000119	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PTK2B—Alzheimer's disease	6.72e-06	0.000119	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GAPDH—Alzheimer's disease	6.71e-06	0.000119	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—TPI1—Alzheimer's disease	6.69e-06	0.000119	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CHAT—Alzheimer's disease	6.69e-06	0.000119	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—APOE—Alzheimer's disease	6.63e-06	0.000118	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—TP53—Alzheimer's disease	6.62e-06	0.000118	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CCR5—Alzheimer's disease	6.59e-06	0.000117	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—NGF—Alzheimer's disease	6.58e-06	0.000117	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—Alzheimer's disease	6.57e-06	0.000117	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—GAB2—Alzheimer's disease	6.54e-06	0.000116	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CCR5—Alzheimer's disease	6.54e-06	0.000116	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—SST—Alzheimer's disease	6.54e-06	0.000116	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NTRK2—Alzheimer's disease	6.54e-06	0.000116	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—CALM1—Alzheimer's disease	6.51e-06	0.000116	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—GSK3A—Alzheimer's disease	6.48e-06	0.000115	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—A2M—Alzheimer's disease	6.48e-06	0.000115	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NGFR—Alzheimer's disease	6.46e-06	0.000115	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—HTR2A—Alzheimer's disease	6.45e-06	0.000115	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—CREB1—Alzheimer's disease	6.42e-06	0.000114	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—MAOB—Alzheimer's disease	6.41e-06	0.000114	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CCR5—Alzheimer's disease	6.4e-06	0.000114	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—HTR2A—Alzheimer's disease	6.4e-06	0.000114	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—APP—Alzheimer's disease	6.37e-06	0.000113	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—ADAM10—Alzheimer's disease	6.31e-06	0.000112	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—CCL2—Alzheimer's disease	6.28e-06	0.000112	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—HTR2A—Alzheimer's disease	6.26e-06	0.000111	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GAPDH—Alzheimer's disease	6.17e-06	0.00011	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—F2—Alzheimer's disease	6.12e-06	0.000109	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—IL6—Alzheimer's disease	6.06e-06	0.000108	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CALM1—Alzheimer's disease	6.01e-06	0.000107	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PLCB1—Alzheimer's disease	6.01e-06	0.000107	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—LEP—Alzheimer's disease	5.99e-06	0.000107	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—APOE—Alzheimer's disease	5.99e-06	0.000107	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CALM1—Alzheimer's disease	5.97e-06	0.000106	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—S100B—Alzheimer's disease	5.96e-06	0.000106	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—A2M—Alzheimer's disease	5.96e-06	0.000106	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—APOE—Alzheimer's disease	5.95e-06	0.000106	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—LEP—Alzheimer's disease	5.95e-06	0.000106	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CAV1—Alzheimer's disease	5.94e-06	0.000106	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CAV1—Alzheimer's disease	5.89e-06	0.000105	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CALM1—Alzheimer's disease	5.84e-06	0.000104	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—APOE—Alzheimer's disease	5.82e-06	0.000104	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—LEP—Alzheimer's disease	5.82e-06	0.000104	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—Alzheimer's disease	5.78e-06	0.000103	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CAV1—Alzheimer's disease	5.77e-06	0.000103	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—ESR1—Alzheimer's disease	5.72e-06	0.000102	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IGF2—Alzheimer's disease	5.68e-06	0.000101	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—ESR1—Alzheimer's disease	5.68e-06	0.000101	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—F2—Alzheimer's disease	5.65e-06	0.0001	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ACHE—Alzheimer's disease	5.64e-06	0.0001	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—F2—Alzheimer's disease	5.61e-06	9.97e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NGFR—Alzheimer's disease	5.61e-06	9.97e-05	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—AKT1—Alzheimer's disease	5.59e-06	9.95e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—CREB1—Alzheimer's disease	5.57e-06	9.91e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—INPP5D—Alzheimer's disease	5.57e-06	9.91e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—ESR1—Alzheimer's disease	5.56e-06	9.88e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—NOTCH1—Alzheimer's disease	5.53e-06	9.83e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IGF1R—Alzheimer's disease	5.49e-06	9.76e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—F2—Alzheimer's disease	5.49e-06	9.76e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—NOTCH1—Alzheimer's disease	5.49e-06	9.76e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ADAM10—Alzheimer's disease	5.48e-06	9.74e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—CCL2—Alzheimer's disease	5.45e-06	9.69e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—NOTCH1—Alzheimer's disease	5.37e-06	9.55e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ENO1—Alzheimer's disease	5.28e-06	9.39e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PTGS1—Alzheimer's disease	5.28e-06	9.39e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—LPL—Alzheimer's disease	5.26e-06	9.36e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MEF2C—Alzheimer's disease	5.22e-06	9.28e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—GSK3B—Alzheimer's disease	5.19e-06	9.23e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ACHE—Alzheimer's disease	5.18e-06	9.22e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—S100B—Alzheimer's disease	5.18e-06	9.21e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CYP2D6—Alzheimer's disease	5.18e-06	9.21e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—GSK3B—Alzheimer's disease	5.15e-06	9.16e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CREB1—Alzheimer's disease	5.15e-06	9.15e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—INPP5D—Alzheimer's disease	5.12e-06	9.11e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—INS—Alzheimer's disease	5.12e-06	9.1e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PRKCG—Alzheimer's disease	5.12e-06	9.1e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CREB1—Alzheimer's disease	5.11e-06	9.08e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—INS—Alzheimer's disease	5.08e-06	9.03e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—GSK3B—Alzheimer's disease	5.04e-06	8.97e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CCL2—Alzheimer's disease	5.04e-06	8.96e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CREB1—Alzheimer's disease	5e-06	8.89e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CCL2—Alzheimer's disease	5e-06	8.89e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NGF—Alzheimer's disease	4.99e-06	8.87e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—INS—Alzheimer's disease	4.97e-06	8.84e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IGF1—Alzheimer's disease	4.95e-06	8.8e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IGF2—Alzheimer's disease	4.93e-06	8.77e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IGF1—Alzheimer's disease	4.91e-06	8.74e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—BCHE—Alzheimer's disease	4.91e-06	8.73e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CCL2—Alzheimer's disease	4.89e-06	8.7e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ENO1—Alzheimer's disease	4.86e-06	8.64e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PTGS1—Alzheimer's disease	4.86e-06	8.64e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CCR5—Alzheimer's disease	4.85e-06	8.62e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IGF1—Alzheimer's disease	4.81e-06	8.55e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IGF1R—Alzheimer's disease	4.77e-06	8.48e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—HTR2A—Alzheimer's disease	4.75e-06	8.44e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PLCB1—Alzheimer's disease	4.63e-06	8.24e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—LPL—Alzheimer's disease	4.57e-06	8.13e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—Alzheimer's disease	4.54e-06	8.08e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MEF2C—Alzheimer's disease	4.53e-06	8.06e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—BCHE—Alzheimer's disease	4.52e-06	8.03e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ABCA1—Alzheimer's disease	4.49e-06	7.98e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—NOS3—Alzheimer's disease	4.49e-06	7.98e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—NOS3—Alzheimer's disease	4.45e-06	7.92e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PRKCG—Alzheimer's disease	4.44e-06	7.9e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CALM1—Alzheimer's disease	4.43e-06	7.87e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—LEP—Alzheimer's disease	4.41e-06	7.85e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—APOE—Alzheimer's disease	4.41e-06	7.85e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CAV1—Alzheimer's disease	4.37e-06	7.77e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CHAT—Alzheimer's disease	4.37e-06	7.77e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—TPI1—Alzheimer's disease	4.37e-06	7.77e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—NOS3—Alzheimer's disease	4.36e-06	7.76e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NGF—Alzheimer's disease	4.33e-06	7.7e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PLCB1—Alzheimer's disease	4.26e-06	7.58e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—ESR1—Alzheimer's disease	4.21e-06	7.49e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CCR5—Alzheimer's disease	4.21e-06	7.49e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—MAOB—Alzheimer's disease	4.19e-06	7.45e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—F2—Alzheimer's disease	4.16e-06	7.4e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ABCA1—Alzheimer's disease	4.13e-06	7.34e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NOTCH1—Alzheimer's disease	4.07e-06	7.24e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GAPDH—Alzheimer's disease	4.03e-06	7.17e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—A2M—Alzheimer's disease	3.9e-06	6.93e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PPARGC1A—Alzheimer's disease	3.87e-06	6.88e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—HMOX1—Alzheimer's disease	3.85e-06	6.85e-05	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—AKT1—Alzheimer's disease	3.85e-06	6.84e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CALM1—Alzheimer's disease	3.85e-06	6.84e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—APOE—Alzheimer's disease	3.83e-06	6.81e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—LEP—Alzheimer's disease	3.83e-06	6.81e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—GSK3B—Alzheimer's disease	3.82e-06	6.79e-05	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—AKT1—Alzheimer's disease	3.82e-06	6.79e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CASP3—Alzheimer's disease	3.81e-06	6.78e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CAV1—Alzheimer's disease	3.8e-06	6.75e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CREB1—Alzheimer's disease	3.79e-06	6.74e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—IL6—Alzheimer's disease	3.79e-06	6.73e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CASP3—Alzheimer's disease	3.78e-06	6.73e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—INS—Alzheimer's disease	3.77e-06	6.7e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—IL6—Alzheimer's disease	3.76e-06	6.68e-05	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—AKT1—Alzheimer's disease	3.74e-06	6.65e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CCL2—Alzheimer's disease	3.71e-06	6.59e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CASP3—Alzheimer's disease	3.7e-06	6.58e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—IL6—Alzheimer's disease	3.68e-06	6.54e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ESR1—Alzheimer's disease	3.66e-06	6.5e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IGF1—Alzheimer's disease	3.65e-06	6.48e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—F2—Alzheimer's disease	3.61e-06	6.43e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PPARGC1A—Alzheimer's disease	3.56e-06	6.33e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—HMOX1—Alzheimer's disease	3.54e-06	6.3e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NOTCH1—Alzheimer's disease	3.54e-06	6.29e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—LPL—Alzheimer's disease	3.52e-06	6.27e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MAPK8—Alzheimer's disease	3.5e-06	6.23e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—AKT1—Alzheimer's disease	3.49e-06	6.21e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MAPK8—Alzheimer's disease	3.48e-06	6.18e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—AKT1—Alzheimer's disease	3.47e-06	6.16e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MAPK8—Alzheimer's disease	3.4e-06	6.05e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—AKT1—Alzheimer's disease	3.39e-06	6.04e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ACHE—Alzheimer's disease	3.39e-06	6.03e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—INPP5D—Alzheimer's disease	3.35e-06	5.96e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—GSK3B—Alzheimer's disease	3.32e-06	5.9e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NOS3—Alzheimer's disease	3.31e-06	5.88e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CREB1—Alzheimer's disease	3.29e-06	5.85e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—INS—Alzheimer's disease	3.27e-06	5.82e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—LPL—Alzheimer's disease	3.24e-06	5.76e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—VEGFA—Alzheimer's disease	3.23e-06	5.75e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CCL2—Alzheimer's disease	3.22e-06	5.73e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—VEGFA—Alzheimer's disease	3.21e-06	5.71e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ENO1—Alzheimer's disease	3.18e-06	5.65e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PTGS1—Alzheimer's disease	3.18e-06	5.65e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—MTHFR—Alzheimer's disease	3.17e-06	5.64e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IGF1—Alzheimer's disease	3.17e-06	5.63e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—VEGFA—Alzheimer's disease	3.14e-06	5.59e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP2D6—Alzheimer's disease	3.11e-06	5.54e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TGFB1—Alzheimer's disease	2.97e-06	5.28e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CALM1—Alzheimer's disease	2.96e-06	5.27e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—APOE—Alzheimer's disease	2.95e-06	5.25e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—BCHE—Alzheimer's disease	2.95e-06	5.25e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TGFB1—Alzheimer's disease	2.95e-06	5.24e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CAV1—Alzheimer's disease	2.93e-06	5.2e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—MTHFR—Alzheimer's disease	2.92e-06	5.19e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TGFB1—Alzheimer's disease	2.88e-06	5.13e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NOS3—Alzheimer's disease	2.87e-06	5.1e-05	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—AKT1—Alzheimer's disease	2.83e-06	5.04e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CASP3—Alzheimer's disease	2.81e-06	4.99e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—IL6—Alzheimer's disease	2.79e-06	4.96e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PLCB1—Alzheimer's disease	2.79e-06	4.95e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CALM1—Alzheimer's disease	2.73e-06	4.85e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—APOE—Alzheimer's disease	2.72e-06	4.83e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ABCA1—Alzheimer's disease	2.7e-06	4.8e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CAV1—Alzheimer's disease	2.69e-06	4.79e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MAPK8—Alzheimer's disease	2.58e-06	4.59e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PPARG—Alzheimer's disease	2.57e-06	4.57e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—AKT1—Alzheimer's disease	2.57e-06	4.57e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—INS—Alzheimer's disease	2.52e-06	4.49e-05	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—AKT1—Alzheimer's disease	2.46e-06	4.37e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TP53—Alzheimer's disease	2.44e-06	4.35e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CASP3—Alzheimer's disease	2.44e-06	4.33e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TP53—Alzheimer's disease	2.43e-06	4.31e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—IL6—Alzheimer's disease	2.42e-06	4.31e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—VEGFA—Alzheimer's disease	2.38e-06	4.23e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TP53—Alzheimer's disease	2.37e-06	4.22e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PPARG—Alzheimer's disease	2.37e-06	4.21e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PPARGC1A—Alzheimer's disease	2.33e-06	4.14e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—INS—Alzheimer's disease	2.32e-06	4.13e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—HMOX1—Alzheimer's disease	2.32e-06	4.12e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MAPK8—Alzheimer's disease	2.24e-06	3.98e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IL6—Alzheimer's disease	2.24e-06	3.98e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—AKT1—Alzheimer's disease	2.23e-06	3.97e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IL6—Alzheimer's disease	2.22e-06	3.95e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—NOS3—Alzheimer's disease	2.21e-06	3.93e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TGFB1—Alzheimer's disease	2.19e-06	3.89e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IL6—Alzheimer's disease	2.17e-06	3.86e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—LPL—Alzheimer's disease	2.12e-06	3.77e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—VEGFA—Alzheimer's disease	2.07e-06	3.68e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—AKT1—Alzheimer's disease	2.06e-06	3.67e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—AKT1—Alzheimer's disease	2.05e-06	3.64e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—NOS3—Alzheimer's disease	2.04e-06	3.62e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PTGS2—Alzheimer's disease	2.02e-06	3.6e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—AKT1—Alzheimer's disease	2.01e-06	3.57e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—MTHFR—Alzheimer's disease	1.91e-06	3.39e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TGFB1—Alzheimer's disease	1.9e-06	3.38e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PTGS2—Alzheimer's disease	1.86e-06	3.31e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TP53—Alzheimer's disease	1.8e-06	3.2e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CALM1—Alzheimer's disease	1.78e-06	3.17e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—APOE—Alzheimer's disease	1.78e-06	3.16e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CAV1—Alzheimer's disease	1.76e-06	3.13e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IL6—Alzheimer's disease	1.65e-06	2.93e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TP53—Alzheimer's disease	1.56e-06	2.78e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PPARG—Alzheimer's disease	1.55e-06	2.75e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—AKT1—Alzheimer's disease	1.52e-06	2.7e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—INS—Alzheimer's disease	1.52e-06	2.7e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IL6—Alzheimer's disease	1.43e-06	2.54e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—NOS3—Alzheimer's disease	1.33e-06	2.37e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—AKT1—Alzheimer's disease	1.32e-06	2.35e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PTGS2—Alzheimer's disease	1.22e-06	2.16e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—AKT1—Alzheimer's disease	1.02e-06	1.81e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—AKT1—Alzheimer's disease	9.36e-07	1.66e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—AKT1—Alzheimer's disease	6.12e-07	1.09e-05	CbGpPWpGaD
